Physician profile
James Norman
NPI 1437411576
$1,544.89
in general payments reported to CMS, 2019-2025
19 companies · $382 in 2025
The $382 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $156 · 2021: $192 · 2022: $268 · 2023: $214 · 2024: $333 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $928.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $242.96 | 2021-2025 | Breztri, Airsupra |
| Abbvie INC. | $202.31 | 2021-2025 | |
| Novo Nordisk INC | $186.38 | 2020-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $151.93 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $144.88 | 2021-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $113.11 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $88.73 | 2020-2024 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $88.38 | 2023-2025 | Rexulti |
| Pfizer INC. | $56.46 | 2020-2024 | |
| Amgen INC. | $46.82 | 2021-2024 | Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.75 | 2025 | Caplyta |
| Lundbeck LLC | $38.72 | 2024 | Rexulti |
| Allergan, INC. | $31.88 | 2020 | |
| Merck Sharp & Dohme LLC | $29.00 | 2020 | |
| Abbott Laboratories | $20.87 | 2025 | Freestyle Libre 3 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.60 | 2022 | |
| Mylan Specialty L.P. | $13.48 | 2022 | |
| Avanir Pharmaceuticals, INC. | $12.41 | 2022 | |
| Eisai INC. | $11.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Norman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.